Final closing Series A
ZURICH, SWITZERLAND – July 10, 2017 – Biovotion Ltd, the award-winning digital health company, is announcing the final closing of its oversubscribed CHF13M Series A financing round. Following earlier closings with Swiss Re as the lead investor (Ticker symbol: SREN) and Harmony Medical Inc., a Hong-Kong based investment company backed by CITIC (HKSE: 00267) of China. The Series A round has now been closed with the addition of the corporate Venture Capital arm of a major global consumer organisation, and a UK based institutional investor with dedicated experiences in the IoT space. Existing investor STMicroelectronics NV (EPA: STM) continued their support and also participated in the round.
The addition of a fourth corporate VC to the shareholder group solidifies Biovotion’s ambition to partner with those committed to driving digital transformation efforts in the medical and health industries. Biovotion continues to promote the decentralisation of healthcare provision, with a focus on empowering end users and patients in a highly scalable and bidirectional manner.
Biovotion is currently unfolding its Machine Learning-supported digital health platform. This consists of the Everion® a unique medical-grade physiological monitoring wearable, in combination with a powerful data analytics engine.
Read more on the unrelenting transformation towards actionable information.
About Biovotion Ltd
Biovotion, based in Switzerland, is a leading wearable physiology monitoring company and provides integrated solutions with connected hardware, value-added data analytics and monitoring services. Designed with the consumer in mind and medical quality at heart, the platform is truly born in the cloud and has been designed from scratch to combine state of the art cybersecurity, GDPR compliance and cloud based services – forming a next generation medical IoT solution. Biovotion’s digital health solutions actively promote the consumerisation of healthcare and supports users in maintaining a healthy lifestyle, improving healthcare treatment outcomes, and aiming to reduce cost burden of health provisions. Biovotion’s wearable solutions have been awarded with multiple international, prestigious prizes and high-calibre endorsements, including an XPrize award in late 2014. Everion® is CE medical class 2a approved as well as FDA 510(k) exempt listed as a medical device. To learn more about Biovotion, visit www.biovotion.com or follow us on Twitter @Biovotion
About Swiss Re
The Swiss Re Group is a leading wholesale provider of reinsurance, insurance and other insurance-based forms of risk transfer. Dealing direct and working through brokers, its global client base consists of insurance companies, mid-to-large-sized corporations and public sector clients. From standard products to tailor-made coverage across all lines of business, Swiss Re deploys its capital strength, expertise and innovation power to enable the risk-taking upon which enterprise and progress in society depend. Founded in Zurich, Switzerland, in 1863, Swiss Re serves clients through a network of around 70 offices globally and is rated "AA-" by Standard & Poor's, "Aa3" by Moody's and "A+" by A.M. Best. Registered shares in the Swiss Re Group holding company, Swiss Re Ltd, are listed in accordance with the International Reporting Standard on the SIX Swiss Exchange and trade under the symbol SREN. For more information about Swiss Re Group, please visit www.swissre.com or follow us on Twitter @SwissRe.